Cargando…

Developing Drugs for Tissue‐Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine

Targeted therapies have reshaped the landscape of the development of cancer therapeutics. Recent biomarker‐driven, tissue‐agnostic clinical trials represent a significant paradigm shift in precision cancer medicine. Despite their growth in preclinical and clinical studies, to date only a few biomark...

Descripción completa

Detalles Bibliográficos
Autores principales: Seligson, Nathan D., Knepper, Todd C., Ragg, Susanne, Walko, Christine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891377/
https://www.ncbi.nlm.nih.gov/pubmed/32535906
http://dx.doi.org/10.1002/cpt.1946

Ejemplares similares